Identification

Name
Propiomazine
Accession Number
DB00777  (APRD00339)
Type
Small Molecule
Groups
Approved
Description

Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.

Structure
Thumb
Synonyms
  • 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine
  • 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine
  • 3-Propionyl-10-dimethylaminoisopropylphenothiazine
  • Propiomazin
  • Propiomazina
  • Propiomazine
  • Propiomazinum
External IDs
CB 1678 / Wy 1359
Product Ingredients
IngredientUNIICASInChI Key
Propiomazine hydrochloride70BO17YR031240-15-9UGVNGSMLNPWNNA-UHFFFAOYSA-N
International/Other Brands
Dorevan / Dorevane / Indorm / Largon / Propavan (Sanofi-Aventis) / Serentin
Categories
UNII
242Z0PM79Y
CAS number
362-29-8
Weight
Average: 340.482
Monoisotopic: 340.16093409
Chemical Formula
C20H24N2OS
InChI Key
UVOIBTBFPOZKGP-UHFFFAOYSA-N
InChI
InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3
IUPAC Name
1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one
SMILES
CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1

Pharmacology

Indication

Propiomazine is largely used for its antihistamininc sleep inducing effects in treating insomnia.

Pharmacodynamics

Although propiomazine is a phenothiazine, it is not used as an antipsychotic. It posesses antihistamine effects and is mostly used as a sedative in treating insomnia.

Mechanism of action

Propiomazine is an antagonist at types 1, 2, and 4 dopamine receptors, serotonin (5-HT) receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Its main use as a sedative is due to its antihistamine effect.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
UD(2) dopamine receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

81%

Metabolism

Unknown, but most likely hepatic as with other phenothiazines.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Rare, serious side effects include convulsions (seizures); difficult or unusually fast breathing; fast or irregular heartbeat or pulse; fever (high); high or low blood pressure; loss of bladder control; muscle stiffness (severe); unusual increase in sweating; unusually pale skin; and unusual tiredness or weakness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Propiomazine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Propiomazine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Propiomazine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Propiomazine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Propiomazine.Experimental, Illicit
4-MethoxyamphetaminePropiomazine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
AcepromazinePropiomazine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AdrafinilPropiomazine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatinePropiomazine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the antihypertensive activities of Propiomazine.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Withdrawn
AmibegronPropiomazine may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
AmitrazPropiomazine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylinePropiomazine may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Amlodipine.Approved
AmoxapinePropiomazine may increase the antihypertensive activities of Amoxapine.Approved
AmphetamineAmphetamine may decrease the sedative activities of Propiomazine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Propiomazine is combined with Amrinone.Approved
AnisodaminePropiomazine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphinePropiomazine may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidinePropiomazine may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Aranidipine.Approved, Investigational
ArbutaminePropiomazine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolPropiomazine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazolePropiomazine may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Propiomazine.Investigational
AsenapinePropiomazine may increase the antihypertensive activities of Asenapine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
AvanafilAvanafil may increase the hypotensive activities of Propiomazine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Propiomazine is combined with Azimilide.Investigational
BambuterolPropiomazine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarnidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Propiomazine.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Propiomazine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Benidipine.Approved, Investigational
BenzphetaminePropiomazine may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
Benzylpenicilloyl PolylysinePropiomazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of hypotension can be increased when Propiomazine is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Propiomazine.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
BevantololPropiomazine may increase the antihypertensive activities of Bevantolol.Approved
BioallethrinThe risk or severity of hypotension can be increased when Propiomazine is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
BitolterolPropiomazine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
BrexpiprazolePropiomazine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidinePropiomazine may decrease the vasoconstricting activities of Brimonidine.Approved
BromocriptinePropiomazine may decrease the vasoconstricting activities of Bromocriptine.Approved, Investigational
BucindololBucindolol may increase the antihypertensive activities of Propiomazine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Propiomazine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Propiomazine.Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Propiomazine is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Propiomazine is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Propiomazine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
ChlorphentermineChlorphentermine may decrease the sedative activities of Propiomazine.Illicit, Withdrawn
ChlorpromazinePropiomazine may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
CilnidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Propiomazine is combined with Cinnarizine.Approved, Investigational
CirazolinePropiomazine may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolPropiomazine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Clevidipine.Approved, Investigational
ClonidinePropiomazine may decrease the vasoconstricting activities of Clonidine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Propiomazine.Experimental
ClozapinePropiomazine may increase the antihypertensive activities of Clozapine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Propiomazine is combined with Cyclandelate.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Propiomazine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Propiomazine.Investigational
DarodipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Darodipine.Experimental
DesipramineDesipramine may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
DetomidinePropiomazine may decrease the vasoconstricting activities of Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Deutetrabenazine.Approved, Investigational
DexmedetomidinePropiomazine may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetaminePropiomazine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative activities of Propiomazine.Approved, Illicit
DihydroergotaminePropiomazine may decrease the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DiltiazemThe risk or severity of hypotension can be increased when Propiomazine is combined with Diltiazem.Approved, Investigational
DipivefrinPropiomazine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Propiomazine.Approved
DL-MethylephedrinePropiomazine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutaminePropiomazine may decrease the vasoconstricting activities of Dobutamine.Approved
DopexaminePropiomazine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DotarizineThe risk or severity of hypotension can be increased when Propiomazine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Propiomazine.Approved
DoxepinPropiomazine may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllinePropiomazine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DronedaronePropiomazine may increase the antihypertensive activities of Dronedarone.Approved
DroperidolPropiomazine may increase the antihypertensive activities of Droperidol.Approved, Vet Approved
DroxidopaPropiomazine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Efonidipine.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Propiomazine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Propiomazine is combined with Eperisone.Approved, Investigational
EphedraPropiomazine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrinePropiomazine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastinePropiomazine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrinePropiomazine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgonovinePropiomazine may decrease the vasoconstricting activities of Ergonovine.Approved
ErgotaminePropiomazine may decrease the vasoconstricting activities of Ergotamine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Propiomazine.Experimental
EscitalopramPropiomazine may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
EtafedrinePropiomazine may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Propiomazine is combined with Ethosuximide.Approved
EtilefrinePropiomazine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidatePropiomazine may decrease the vasoconstricting activities of Etomidate.Approved
FelodipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Propiomazine is combined with Fendiline.Withdrawn
FenoterolPropiomazine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Propiomazine is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Propiomazine is combined with Flunarizine.Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Propiomazine.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Propiomazine is combined with Fluspirilene.Approved, Investigational
FormoterolPropiomazine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Propiomazine.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Propiomazine is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Propiomazine is combined with Gallopamil.Investigational
GepefrineGepefrine may decrease the sedative activities of Propiomazine.Experimental
GuanabenzPropiomazine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacinePropiomazine may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
HexoprenalinePropiomazine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenaminePropiomazine may decrease the vasoconstricting activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Propiomazine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Propiomazine.Approved
IloperidonePropiomazine may increase the antihypertensive activities of Iloperidone.Approved
ImipraminePropiomazine may increase the antihypertensive activities of Imipramine.Approved
IndacaterolPropiomazine may decrease the vasoconstricting activities of Indacaterol.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Propiomazine.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Propiomazine.Withdrawn
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Propiomazine.Approved
IsoetarinePropiomazine may decrease the vasoconstricting activities of Isoetarine.Approved
IsometheptenePropiomazine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalinePropiomazine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprinePropiomazine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Isradipine.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Propiomazine.Approved
LacidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Propiomazine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Propiomazine.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Propiomazine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
LevosalbutamolPropiomazine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Lidoflazine.Experimental
LisdexamfetaminePropiomazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LofexidinePropiomazine may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Propiomazine is combined with Loperamide.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Propiomazine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Manidipine.Approved, Investigational
MedetomidinePropiomazine may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MentholThe risk or severity of hypotension can be increased when Propiomazine is combined with Menthol.Approved
MephedroneMephedrone may decrease the sedative activities of Propiomazine.Investigational
MephenterminePropiomazine may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Propiomazine.Experimental
MetaraminolPropiomazine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethamphetaminePropiomazine may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethotrimeprazinePropiomazine may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
MethoxaminePropiomazine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenaminePropiomazine may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Propiomazine is combined with Methsuximide.Approved
MethyldopaPropiomazine may decrease the vasoconstricting activities of Methyldopa.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Propiomazine is combined with Mibefradil.Investigational, Withdrawn
MidodrinePropiomazine may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineMidomafetamine may decrease the sedative activities of Propiomazine.Experimental, Illicit, Investigational
MirabegronPropiomazine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Propiomazine.Investigational
MMDAMMDA may decrease the sedative activities of Propiomazine.Experimental, Illicit
MoxonidinePropiomazine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Propiomazine is combined with Naftopidil.Investigational
NaphazolinePropiomazine may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
NefazodonePropiomazine may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NicardipinePropiomazine may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Propiomazine.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nifedipine.Approved
NiguldipinePropiomazine may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Propiomazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nitrendipine.Approved, Investigational
NorepinephrinePropiomazine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrinePropiomazine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylinePropiomazine may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinPropiomazine may decrease the vasoconstricting activities of Nylidrin.Approved
OctopaminePropiomazine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapinePropiomazine may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlodaterolPropiomazine may decrease the vasoconstricting activities of Olodaterol.Approved
OrciprenalinePropiomazine may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Propiomazine is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
OxyfedrinePropiomazine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolinePropiomazine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PaliperidonePropiomazine may increase the antihypertensive activities of Paliperidone.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
PentoxifyllinePentoxifylline may increase the hypotensive activities of Propiomazine.Approved, Investigational
PergolidePropiomazine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PhendimetrazinePropiomazine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Propiomazine.Approved
PhenterminePhentermine may decrease the sedative activities of Propiomazine.Approved, Illicit
PhentolaminePropiomazine may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrinePropiomazine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolaminePropiomazine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinaveriumThe risk or severity of hypotension can be increased when Propiomazine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
PirbuterolPropiomazine may decrease the vasoconstricting activities of Pirbuterol.Approved
PizotifenPropiomazine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Propiomazine.Experimental
PractololPractolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
PrazosinPrazosin may increase the antihypertensive activities of Propiomazine.Approved
PrenalterolPropiomazine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Propiomazine is combined with Prenylamine.Withdrawn
ProcaterolPropiomazine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazinePromazine may increase the antihypertensive activities of Propiomazine.Approved, Vet Approved
PropafenonePropafenone may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropericiazinePropiomazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiverinePropiomazine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropranololPropranolol may increase the orthostatic hypotensive activities of Propiomazine.Approved, Investigational
ProtokylolPropiomazine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PseudoephedrinePropiomazine may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapinePropiomazine may increase the antihypertensive activities of Quetiapine.Approved
QuinidinePropiomazine may increase the antihypertensive activities of Quinidine.Approved, Investigational
RacepinephrinePropiomazine may increase the antihypertensive activities of Racepinephrine.Approved
RactopaminePropiomazine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
ReproterolPropiomazine may decrease the vasoconstricting activities of Reproterol.Investigational
RilmenidinePropiomazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolPropiomazine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Propiomazine.Approved, Investigational
RitobegronPropiomazine may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrinePropiomazine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RomifidinePropiomazine may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopinirolePropiomazine may decrease the vasoconstricting activities of Ropinirole.Approved, Investigational
SalbutamolPropiomazine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolPropiomazine may decrease the vasoconstricting activities of Salmeterol.Approved
SeletracetamThe risk or severity of hypotension can be increased when Propiomazine is combined with Seletracetam.Investigational
SildenafilSildenafil may increase the hypotensive activities of Propiomazine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Propiomazine.Approved
SolabegronPropiomazine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Propiomazine.Approved
SynephrinePropiomazine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Propiomazine.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Propiomazine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Propiomazine.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Propiomazine.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Propiomazine.Approved
TerodilineThe risk or severity of hypotension can be increased when Propiomazine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Propiomazine.Experimental
TetrahydropalmatineThe risk or severity of hypotension can be increased when Propiomazine is combined with Tetrahydropalmatine.Investigational
TetryzolinePropiomazine may decrease the vasoconstricting activities of Tetryzoline.Approved
TheophyllineTheophylline may increase the hypotensive activities of Propiomazine.Approved
ThioproperazinePropiomazine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Propiomazine.Approved, Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
TizanidinePropiomazine may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Propiomazine.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Propiomazine is combined with Tolfenamic Acid.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Propiomazine is combined with Tranilast.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Propiomazine.Approved, Investigational
TretoquinolPropiomazine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrifluoperazinePropiomazine may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Propiomazine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Propiomazine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Propiomazine is combined with Trimethadione.Approved
TrimipraminePropiomazine may increase the antihypertensive activities of Trimipramine.Approved
TulobuterolPropiomazine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Propiomazine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Propiomazine.Investigational
VardenafilVardenafil may increase the hypotensive activities of Propiomazine.Approved
VerapamilPropiomazine may increase the antihypertensive activities of Verapamil.Approved
VilanterolPropiomazine may decrease the vasoconstricting activities of Vilanterol.Approved
VinpocetineThe risk or severity of hypotension can be increased when Propiomazine is combined with Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Propiomazine is combined with WIN 55212-2.Experimental
XamoterolPropiomazine may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazinePropiomazine may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolinePropiomazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Propiomazine is combined with Ziconotide.Approved
ZiprasidoneZiprasidone may increase the antihypertensive activities of Propiomazine.Approved
ZonisamideThe risk or severity of hypotension can be increased when Propiomazine is combined with Zonisamide.Approved, Investigational
ZuclopenthixolPropiomazine may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014915
KEGG Drug
D02361
KEGG Compound
C07405
PubChem Compound
4940
PubChem Substance
46506205
ChemSpider
4771
ChEBI
8491
ChEMBL
CHEMBL1201210
Therapeutic Targets Database
DAP000327
PharmGKB
PA164778685
Wikipedia
Propiomazine
ATC Codes
N05CM06 — Propiomazine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Hr cenci laboratories inc
  • Baxter healthcare corp anesthesia critical care
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility0.454 mg/LNot Available
logP4.79BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00703 mg/mLALOGPS
logP4.53ALOGPS
logP4.55ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)16.64ChemAxon
pKa (Strongest Basic)8.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity103.53 m3·mol-1ChemAxon
Polarizability38.62 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier+0.9837
Caco-2 permeable+0.796
P-glycoprotein substrateSubstrate0.8544
P-glycoprotein inhibitor IInhibitor0.9338
P-glycoprotein inhibitor IINon-inhibitor0.7772
Renal organic cation transporterNon-inhibitor0.5594
CYP450 2C9 substrateNon-substrate0.8106
CYP450 2D6 substrateSubstrate0.7113
CYP450 3A4 substrateSubstrate0.5966
CYP450 1A2 substrateInhibitor0.8364
CYP450 2C9 inhibitorNon-inhibitor0.8827
CYP450 2D6 inhibitorInhibitor0.7359
CYP450 2C19 inhibitorNon-inhibitor0.8787
CYP450 3A4 inhibitorNon-inhibitor0.7492
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5182
Ames testNon AMES toxic0.8431
CarcinogenicityNon-carcinogens0.8384
BiodegradationNot ready biodegradable0.993
Rat acute toxicity2.7773 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9731
hERG inhibition (predictor II)Inhibitor0.6987
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.28 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-00di-9100000000-976e369803cbbc61ad7a
Mass Spectrum (Electron Ionization)MSsplash10-00di-9220000000-31dfa9c2a3e2a6046ef7
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Aryl alkyl ketones / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Aryl alkyl ketone / Aryl ketone / Para-thiazine / Benzenoid / Ketone
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, tertiary amino compound, aromatic ketone (CHEBI:8491)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. KRAKOWSKI AJ: Propiomazine for control of insomnia in nervous disorders. Am J Psychiatry. 1962 Nov;119:461-2. [PubMed:14035428]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 09:39